CARA's IV Korsuva for the treatment of severe itching (pruritus) in CKD patients on dialysis has a PDUFA date of August 23, 2021. It appears that the FDA does not have issues with IV Korsuva's ...

A new deal with a major dialysis provider could propel Korsuva much further than expected. A new partnership with leading dialysis providers could be a huge advantage, but the company's lead ...

--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Cara Therapeutics (Nasdaq:CARA) today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA ...

TDAPA will apply to KORSUVA injection beginning April 4, 2022, for two years. KORSUVA injection was approved by the U.S. Food and Drug Administration (FDA) in August 2021 for the treatment of ...

Cara’s flagship product, Korsuva (difelikefalin), is the first and only FDA-approved treatment for moderate-to-severe pruritus in adult patients with chronic kidney disease who are on dialysis ...

Stamford, Connecticut-based Cara will commercialize its new drug under the name “Korsuva.” According to the National Kidney Foundation, more than 500,000 people in the U.S. receive dialysis to ...

Hemodialysis was found to be a poor prognostic factor for patients with RCC. The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 ...

placebo after 12-week treatment period (p=0.018) – – Oral KORSUVA™ well-tolerated after 12 weeks of treatment – – Conference call today at 8:30 a.m. ET – STAMFORD, Conn., Dec. 03 ...

During the Kalm-1 study, 51% of patients given Korsuva achieved a three-point or better improvement to their worst itch intensity scores compared to just 28% of those in the placebo group.

Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system ...

Cara Therapeutics expects to announce results in the second quarter from a phase 3 clinical study evaluating its lead candidate, Korsuva injection, in treating chronic kidney disease-associated ...

Hemodialysis was found to be a poor prognostic factor for patients with RCC. The approval was based on data from the pivotal phase 3 KALM-1 and KALM-2 trials, as well as data from an additional 32 ...